Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer

Abstract

Human epidermal growth factor 2 (HER2)-positive breast cancer (BC) represents nearly 20% of all breast tumors. Historically, these patients had a high rate of relapse and dismal prognosis. The advent of HER2-targeting monoclonal antibodies such as trastuzumab followed by pertuzumab had improved the prognosis of HER2-positive metastatic BC. More recently, antibody-drug conjugates (ADCs) are now reshaping the treatment paradigm of solid tumors, especially breast cancer. Tratsuzumab emtansine (T-DM1) was one of the first ADC developed in oncology and was approved for the management of HER2-positive metastatic BC. In a head-to-head comparison, trastuzumab deruxtecan (T-DXd) defeated T-DM1 as a second-line treatment. The efficacy of ADCs is counterbalanced by the appearance of acquired resistance to these agents. In this paper, we summarize the mechanisms of action and resistance of T-DM1 and T-DXd, as well as their clinical efficacy. Additionally, we also discuss potential strategies for addressing resistance to ADC.

Keywords

Trastuzumab / pertuzumab / trastuzumab emtansine / antibody-drug conjugate (ADC) / trastuzumab deruxtecan / metastatic breast cancer / HER2 / resistance

References

[1] Siegel RL,Fuchs HE.Cancer statistics, 2022.CA Cancer J Clin2022;72:7-33

[2] Pauletti G,Press MF.Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.Oncogene1996;13:63-72

[3] Yarden Y.Untangling the ErbB signalling network.Nat Rev Mol Cell Biol2001;2:127-37

[4] Spector NL.Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.J Clin Oncol2009;27:5838-47

[5] Choong GM,O’Sullivan CC.Evolving standards of care and new challenges in the management of HER2-positive breast cancer.CA Cancer J Clin2020;70:355-74

[6] Slamon DJ,Shak S.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med2001;344:783-92

[7] Swain SM, Baselga J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372:724-34. PMCID:PMC5584549

[8] Gianni L,Im YH.Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.Lancet Oncol2012;13:25-32

[9] Guidi L,Tarantino P,Curigliano G.Resistance to antibody-drug conjugates targeting HER2 in breast cancer: molecular landscape and future challenges.Cancers2023;15:1130 PMCID:PMC9954056

[10] Verma S, Miles D, Gianni L, et al; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91. PMCID:PMC5125250

[11] Diéras V,Verma S.Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.Lancet Oncol2017;18:732-42 PMCID:PMC5531181

[12] Cortés J, Kim SB, Chung WP, et al; DESTINY-Breast03 Trial Investigators. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 2022;386:1143-54.

[13] Hurvitz SA,Chung WP.Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.Lancet2023;401:105-17

[14] Chau CH,Figg WD.Antibody-drug conjugates for cancer.Lancet2019;394:793-804

[15] Criscitiello C,Curigliano G.Antibody-drug conjugates in solid tumors: a look into novel targets.J Hematol Oncol2021;14:20 PMCID:PMC7844898

[16] Hoffmann RM,Josephs DH.Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs).Oncoimmunology2018;7:e1395127 PMCID:PMC5769674

[17] De Cecco M, Galbraith DN, McDermott LL. What makes a good antibody-drug conjugate?.Expert Opin Biol Ther2021;21:841-7

[18] Chang HL,McArthur HL.Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response.J Clin Invest2023;133:e172156 PMCID:PMC10503805

[19] Diamantis N.Antibody-drug conjugates - an emerging class of cancer treatment.Br J Cancer2016;114:362-7 PMCID:PMC4815767

[20] Jain N,Ghone S.Current ADC linker chemistry.Pharm Res2015;32:3526-40 PMCID:PMC4596905

[21] Drago JZ,Chandarlapaty S.Unlocking the potential of antibody-drug conjugates for cancer therapy.Nat Rev Clin Oncol2021;18:327-44 PMCID:PMC8287784

[22] Lu J,Lu A.Linkers having a crucial role in antibody-drug conjugates.Int J Mol Sci2016;17:561 PMCID:PMC4849017

[23] Khoury R,Khalife N.Mechanisms of resistance to antibody-drug conjugates.Int J Mol Sci2023;24:9674 PMCID:PMC10253543

[24] Sun X,Yoder NC.Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates.Bioconjug Chem2017;28:1371-81

[25] Junttila TT,Parsons K,Sliwkowski MX.Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.Breast Cancer Res Treat2011;128:347-56

[26] Lewis Phillips GDL,Dugger DL.Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.Cancer Res2008;68:9280-90

[27] Hunter FW,Lipert B.Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.Br J Cancer2020;122:603-12 PMCID:PMC7054312

[28] Perez EA,Eiermann W.Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study.J Clin Oncol2017;35:141-8 PMCID:PMC5455677

[29] Hurvitz SA,Symmans WF.Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.Lancet Oncol2018;19:115-26

[30] Hurvitz SA,Jung KH.Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study.J Clin Oncol2019;37:2206-16 PMCID:PMC6774816

[31] von Minckwitz G, Huang CS, Mano MS, et al; KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019;380:617-28.

[32] Ogitani Y,Hagihara K.DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1.Clin Cancer Res2016;22:5097-108

[33] Yver A,Soria JC.The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers.Ann Oncol2020;31:430-4

[34] Modi S, Saura C, Yamashita T, et al; DESTINY-Breast01 Investigators. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 2020;382:610-21. PMCID:PMC7458671

[35] André F,Kim SB.Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.Lancet2023;401:1773-85

[36] Modi S, Jacot W, Yamashita T, et al; DESTINY-Breast04 Trial Investigators. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387:9-20. PMCID:PMC10561652

[37] Bartsch R,Furtner J.Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.Nat Med2022;28:1840-7 PMCID:PMC9499862

[38] Pérez-García JM,Cortez P.Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.Neuro Oncol2023;25:157-66 PMCID:PMC9825345

[39] Jerusalem G,Yamashita T.Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: a DESTINY-Breast01 subgroup analysis.Cancer Discov2022;12:2754-62 PMCID:PMC9716244

[40] Jacobson A.Trastuzumab deruxtecan improves progression-free survival and intracranial response in patients with HER2-positive metastatic breast cancer and brain metastases.Oncologist2022;27:S3-4 PMCID:PMC8963137

[41] Venetis K,Sajjadi E.HER2 Low, Ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer.Front Mol Biosci2022;9:834651 PMCID:PMC8965450

[42] Loganzo F,Sung M.Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.Mol Cancer Ther2015;14:952-63

[43] Filho OM,Stein S.Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab.Cancer Discov2021;11:2474-87 PMCID:PMC8598376

[44] Gebhart G,Wimana Z.Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.Ann Oncol2016;27:619-24

[45] Scaltriti M,Ocaña A.Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.J Natl Cancer Inst2007;99:628-38

[46] Phillips GD,Li G.Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.Clin Cancer Res2014;20:456-68

[47] Schwarz LJ,Rexer BN.An ERBB1-3 neutralizing antibody mixture with high activity against drug-resistant HER2+ breast cancers with ERBB ligand overexpression.J Natl Cancer Inst2017;109:djx065 PMCID:PMC6543617

[48] Zhang M,Liao H.Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft.Cell Death Discov2022;8:478 PMCID:PMC9719506

[49] Yu SF,Go M.A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs.Clin Cancer Res2015;21:3298-306

[50] Takegawa N,Yonesaka K.DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.Int J Cancer2017;141:1682-9

[51] Kalim M,Wang S.Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.Drug Des Devel Ther2017;11:2265-76 PMCID:PMC5546728

[52] Sung M,Lu B.Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1).Mol Cancer Ther2018;17:243-53

[53] Mayor S.Pathways of clathrin-independent endocytosis.Nat Rev Mol Cell Biol2007;8:603-12

[54] Indira Chandran V,Barbachowska M.Hypoxia attenuates trastuzumab uptake and trastuzumab-emtansine (T-DM1) cytotoxicity through redistribution of phosphorylated caveolin-1.Mol Cancer Res2020;18:644-56

[55] Pereira PMR,Carter LM.Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy.Nat Commun2018;9:5137 PMCID:PMC6277446

[56] Baldassarre T,Craig AW.Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.Breast Cancer Res2017;19:110 PMCID:PMC5627411

[57] Ríos-Luci C,Díaz-Rodríguez E.Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity.Cancer Res2017;77:4639-51

[58] Hamblett KJ,Gurgel JL.SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm.Cancer Res2015;75:5329-40

[59] Mosele F,Lusque A.Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.Nat Med2023;29:2110-20 PMCID:PMC10427426

[60] Yu M,Tannock IF.Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?.Cancer Metastasis Rev2013;32:211-27

[61] Lambert JM.Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.J Med Chem2014;57:6949-64

[62] Li G,Shen BQ.Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells.Mol Cancer Ther2018;17:1441-53

[63] Berns K,Hennessy BT.A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.Cancer Cell2007;12:395-402

[64] Baselga J,Verma S.Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer.Clin Cancer Res2016;22:3755-63 PMCID:PMC5485412

[65] Wu Y,Kim J.Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.Mol Cancer Res2012;10:1597-606 PMCID:PMC3732195

[66] Yao L,Ma W.Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements.Front Oncol2023;13:1292211 PMCID:PMC10635515

[67] Gion M,Pérez-García JM.Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.Breast Cancer Res Treat2024;205:589-98

[68] Arthi M,D’Cruze L,Joseph LD.The significance of topoisomerase II alpha in invasive breast carcinoma.Cureus2021;13:e18733 PMCID:PMC8586823

[69] Fountzilas G,Kotoula V.HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.J Transl Med2012;10:10 PMCID:PMC3275536

[70] Durbin KR,Liao X.Mechanistic modeling of antibody-drug conjugate internalization at the cellular level reveals inefficient processing steps.Mol Cancer Ther2018;17:1341-51

[71] Banerji U,Saura C.Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.Lancet Oncol2019;20:1124-35

[72] Aftimos P,O'shaughnessy J.386MO Trastuzumab duocarmazine versus physician’s choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial.Ann Oncol2023;34:S340-1

[73] Yao H,Tong Z.Abstract CT175: Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: a global phase 1, multi-center, first-in-human study.Cancer Res2023;83:CT175

[74] Zhang J,Gao S.Phase I study of A166, an antibody-drug conjugate in advanced HER2-expressing solid tumours.NPJ Breast Cancer2023;9:28 PMCID:PMC10113253

[75] Pourjamal N,Halme A.Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.Clin Exp Metastasis2024;41:91-102 PMCID:PMC10973002

[76] Wang J,Zhang Q.RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies.J Clin Oncol2021;39:1022

[77] Le Joncour V,Puhka M.A novel anti-HER2 antibody-drug conjugate XMT-1522 for HER2-positive breast and gastric cancers resistant to trastuzumab emtansine.Mol Cancer Ther2019;18:1721-30

[78] Skidmore L,Knudsen NA.ARX788, a site-specific anti-HER2 antibody-drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers.Mol Cancer Ther2020;19:1833-43

[79] Barok M,Martins A.ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.Cancer Lett2020;473:156-63

[80] Hu X,Ji D.Abstract P1-18-16: A phase 1 study of ARX788, a HER2-targeting antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer.Cancer Res2020;80:P1-18-16

[81] ACE-breast-02 pivotal phase 3 study of Ambrx’s ARX788 for the treatment of HER2 positive metastatic breast cancer achieves positive results. Available from: https://ir.ambrx.com/news/news-details/2023/ACE-Breast-02-Pivotal-Phase-3-Study-of-Ambrxs-ARX788-for-the-Treatment-of-HER2-Positive-Metastatic-Breast-Cancer-Achieves-Positive-Results/default.aspx. [Last accessed on 11 May 2024]

[82] Li JY,Muniz-Medina V.A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy.Cancer Cell2016;29:117-29

[83] Jhaveri K,Dotan E.460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers.Ann Oncol2022;33:S749-50

[84] Zhong H,Huang H.Preclinical antitumor activity of an anti-HER2/Trop-2 bispecific antibody-drug conjugate with a new DNA topoisomerase I inhibitor.J Clin Oncol2023;41:e15013

[85] Krop IE,Mukohara T.Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, phase I/II trial.J Clin Oncol2023;41:5550-60 PMCID:PMC10730028

[86] Schram AM,Kim D.Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.J Clin Oncol2022;40:105

[87] de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth.Cancer Cell2023;41:374-403

[88] Andersen MH.Tumor microenvironment antigens.Semin Immunopathol2023;45:253-64 PMCID:PMC10335965

[89] Ziogas DC,Lialios PP.Beyond CTLA-4 and PD-1 inhibition: novel immune checkpoint molecules for melanoma treatment.Cancers2023;15:2718 PMCID:PMC10216291

[90] Ceci C,Graziani G.Antibody-drug conjugates: resurgent anticancer agents with multi-targeted therapeutic potential.Pharmacol Ther2022;236:108106

[91] Goodman A. HER2CLIMB-02: Tucatinib plus T-DM1 extends progression-free survival vs T-DM1 alone in advanced HER2-positive breast cancer - the ASCO post. 2023. Available from: https://ascopost.com/issues/december-25-2023/tucatinib-plus-t-dm1-extends-progression-free-survival-vs-t-dm1-alone-in-advanced-her2-positive-breast-cancer/. [Last accessed on 11 May 2024]

[92] Emens LA,Beresford M.Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.Lancet Oncol2020;21:1283-95

[93] Loi S,Song E.329TiP KATE3: a phase III study of trastuzumab emtansine (T-DM1) in combination with atezolizumab or placebo in patients with previously treated HER2-positive and PD-L1-positive locally advanced or metastatic breast cancer.Ann Oncol2021;32:S509

[94] Hurvitz SA,Bianchini G.ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.Future Oncol2022;18:3563-72

[95] Hamilton E,Petrylak D.Abstract PD3-07: trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: a 2-part, phase 1b, multicenter, open-label study.Cancer Res2021;81:PD3-07

[96] Curigliano G,Borges V.Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.Ann Oncol2022;33:321-9